# Legend Bio rises after early-stage data for in vivo CAR-T therapy.

*biotech · news · 2026-06-02 · Seeking Alpha*

## Key points

- Legend Biotech's LB2501 is an in vivo CAR-T therapy targeting B-cell non-Hodgkin lymphoma.
- LB2501 showed initial positive results in an early-stage human clinical trial.
- Legend Biotech's stock rose approximately 26% following the trial announcement.
- LB2501 represents a novel approach by delivering CAR-T therapy directly in vivo.

Legend Bio rises after early-stage data for in vivo CAR-T therapy Jun 02, 2026, 11:07 AM ETLigand Pharmaceuticals Incorporated (LGND) StockBy : Dulan Lokuwithana, SA News Editor Comment (1) Legend Biotech (LGND) added ~26% in the morning hours on Tuesday after announcing initial results from an early-stage trial for LB2501, its in vivo CAR-T cell therapy targeting B-cell non-Hodgkin lymphoma, the most common form of non-Hodgkin lymphoma. Citing data Newsletters for Every Investor Get daily, sector-specific newsletters packed with expert insights, fresh ideas, and new opportunities. Subscribe to Newsletters

**Companies:** Legend Biotech, Ligand Pharmaceuticals Incorporated

[Read the full story on Seeking Alpha](https://seekingalpha.com/news/4599842-legend-bio-posts-early-stage-data-car-t-drug)

---

Canonical: https://newsio.io/n/801d3b13-8727-42a7-9a2c-7119a2a0101b/legend-bio-rises-after-early-stage-data-for-in-vivo-car-t-therapy
Summarized by Newsio from Seeking Alpha. https://newsio.io/how-it-works